Litigation Details for Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)
✉ Email this page to a colleague
Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)
| Docket | See Plans and Pricing | Date Filed | 2014-09-03 |
| Court | District Court, D. Delaware | Date Terminated | 2020-09-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Mitchell S. Goldberg |
| Jury Demand | None | Referred To | |
| Parties | ALEMBIC PHARMACEUTICALS LTD. | ||
| Patents | 7,741,358; 8,022,228 | ||
| Attorneys | Azy S. Kokabi | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Forest Laboratories LLC v. Sigmapharm Laboratories LLC
The small molecule drug covered by the patents cited in this case is See Plans and Pricing .
Details for Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-03-28 | and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228 (Hikma and West-Ward), filed… 14 September 2020 1:14-cv-01119 830 Patent None District Court, D. Delaware | External link to document | ||
| 2014-09-03 | 1 | paragraphs 1-20. 22, United States Patent No. 7,741,358 (“the ’358 patent”), titled “Crystal Forrn of Asenapine…United States Patent No. 7,741,358 constitute infringement of one or more claims of said patent under 35 U.S.C…: a) declare that United States Patent Nos. 5,763,476 and 7,741,358 are valid; b) declare that, under…Sigmapharm infringed United States Patent Nos. 5,763,476 and 7,741,358 by submitting ANDA No. 206107 to …expiration date of United States Patent Nos. 5,763,476 and 7,741,358, including any exclusivities or extensions | External link to document | |
| 2016-01-28 | 133 | language of U.S. Patent Nos. 5,763,476, (the '476 patent), 7,741,358 (the '358 patent), and 8,022,228…1 of the '228 patent which shares a specification with the '358 patent. All references in …8,022,228 (the '228 patent) shall be construed consistent with the tenets of claim construction … The '476 Patent 1. "Tension, excitation, anxiety…the time, evidenced by applicants' separate patent application (No. 11/247,342) for the treatment | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
